Please note: The information displayed on this page might be outdated.
Oryzon Genomics: Developing treatments for the underlying causes of cancer and CNS diseases by targeting lysine specific demethylase 1 (LSD1, aka KDM1A), an epigenetic histone modifying enzyme. Lead CNS compound ORY-2001 is now in three Phase IIa trials in MS, AD and in a basket trial in aggression. Oncology compound, ORY-1001, is in two combo Phase IIa trials in AML and SCLC. Expected data in mid 2019. Oryzon is one of the most liquid small-cap stocks in the Spanish Main market.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Central Nervous System, Oncology
Finance
Pre-earnings, Revenues
Industry
Biotechnology
Listing
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Gene Therapy, Platform Technology, Small Molecule
Website:
Address:
08940 Cornellà de Llobregat
Barcelona
Spain

Company Participants at Jefferies Global Healthcare Conference London Nov 2018

  • Dr. Carlos Buesa, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.